ArticleOsteoarthritis and cartilage2023
Intra-articular kinetics of a cartilage targeting cationic PEGylated protein for applications in drug delivery.
Article in Osteoarthritis and cartilage, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 18 citations in OpenAlex.
- Achondroplasia: Current Disease-Modifying Therapies and Genome Editing Strategies.International journal of molecular sciences · 2026Review
- Protein-based nanocarrier delivering kartogenin derivative to cartilage matrix for intra-articular treatment of osteoarthritis.Journal of drug delivery science and technology · 2026Article
- Engineered cationic Interleukin-1 receptor antagonist outperforms anakinra at joint retention and preventing IL-1-induced cartilage inflammation.Osteoarthritis and cartilage · 2026Article
- Design and Characterization of Gold Nanorod Hyaluronic Acid Hydrogel Nanocomposites for NIR Photothermally Assisted Drug Delivery.Gels (Basel, Switzerland) · 2026Article
- Diabetes-Related Metabolic Osteoarthritis: Advanced Glycation-Collagen Axis, Cartilage Stiffening, and Biomaterials-Based Therapeutic Strategies.International journal of nanomedicine · 2026Review
- Article
- Extended osteoarthritis pain relief with neosaxitoxin using alginate-core polymeric microparticles.Nanoscale · 2025Article
- Spatial charge-hydrophobicity configuration modulates cationic peptide transport in cartilage.Biophysical journal · 2025Article
- Cartilage-targeting exosomes for delivery of receptor antagonist of interleukin-1 in osteoarthritis treatment.Osteoarthritis and cartilage · 2025Article
- Cartilage targeting cationic peptide carriers display deep cartilage penetration and retention in a rabbit model of post-traumatic osteoarthritis.Osteoarthritis and cartilage · 2025Article
- Drug Delivery Systems Targeting the Knee Microenvironment: A Prospective Strategy for Knee Osteoarthritis Treatment.Drug design, development and therapy · 2025Review
- Article
- Harnessing exosomes for advanced osteoarthritis therapy.Nanoscale · 2024Review
- Charge-Reversed Exosomes for Targeted Gene Delivery to Cartilage for Osteoarthritis Treatment.Small methods · 2024Article
- Cationic-motif-modified exosomes for mRNA delivery to retinal photoreceptors.Journal of materials chemistry. B · 2024Article
- Branched poly-l-lysine for cartilage penetrating carriers.Bioengineering & translational medicine · 2024Article
- Sustained intra-cartilage delivery of interleukin-1 receptor antagonist using cationic peptide and protein-based carriers.Osteoarthritis and cartilage · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesCartilage targeting cationic glycoprotein Avidin was PEGylated to synthesize a multi-arm Avidin (mAv) nano-construct with high drug loading content. Here we investigate mAv biodistribution and kinetics over a 7-day period following intra-articular (IA) administration in rat knee joints.
methodsLabeled mAv was injected into healthy rat knees, and joint tissues (articular cartilage, menisci, ligaments, tendons, fat pad) were harvested following sacrifice at 6 h, 1, 4 and 7 days. Its IA biodistribution and retention were measured using fluorescence microscopy. Tissue localization was compared in young vs old rats by immunohistochemistry. mAv chondrotoxicity and immune response were evaluated to determine safe carrier dose limits.
resultsmAv penetrated through the full thickness of rat cartilage and other joint tissues within 6 h, remaining detectable within most joint tissues over 7 days. Intra-tissue uptake correlated strongly with tissue GAG concentration, confirming the dominant role of electrostatic interactions between positively charged mAv and the negatively charged aggrecan proteoglycans. mAv was uptaken by chondrocytes and also penetrated the osteocyte lacuno-canalicular system of peri-articular bone in both young and old rats. mAv did not cause cytotoxicity at concentrations up to 300 μM but elicited a dose dependent immunogenic response.
conclusionsmAv's ability to target a variety of joint tissues, chondrocytes, and peri-articular osteocytes without sequestration in synovial fluid makes it a versatile carrier for delivering a wide range of drugs for treating a broad class of musculoskeletal diseases. Drugs can be conjugated using simple aqueous based avidin-biotin reaction, supporting its clinical prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.